TRAW Stock News & Analysis | Latest Updates

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

NEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced plans to host a conference call and webcast on Thursday, August 14, 2025 at 8:30 AM ET to discuss financial results for the second quarter ended June 30, 2025 and recent business progress.

August 8, 2025Earnings

TRAW News

Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025

Traws Pharma Publishes Key Clinical Efficacy Data For Rigosertib, Oncology Asset For Which Development And Commercialization Partners Are Being Actively Sought, In Patients With RDEB SCC

Traws Pharma Receives Written Responses To Questions Submitted For Type B Pre- Investigational NDA Meeting On Tivoxavir Marboxil

UPDATE: Traws Pharma Q1 Adj. EPS $(1.58) Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate

Traws Pharma Q1 EPS $2.09 Beats $(8.04) Estimate, Sales $57.00K Miss $60.00K Estimate

Traws Pharma Werner Cautreels To retire As CEO; Iain D. Dukes, D Phil, Executive Board Chairman, To Become Interim CEO, Effective On Or About Close Of Business On March 31, 2025

Traws Pharma To Unveil Next-Gen Oral Antivirals for Bird Flu And COVID-19 At March 31 Investor Event

Traws Reports Topline Results From Study Evaluating The Use Of Tivoxavir Marboxil As Treatment For Non-human Primates Challenged With Non-lethal Dose Of H5N1 Bird Flu; Results Build On Earlier Findings Of Mortality Benefit For TXM In Ferrets And Mice

Traws Pharma Presents Bird Flu Data For Tivoxavir Marboxil At ICAR, Highlighting 100% Survival In Rodent Model And Strong Phase 1 Results

Traws Pharma Announced Topline Results From Ferrets Infected With H5N1 Bird Flu, An Accepted Animal Model For Human Influenza, When Treated With Tivoxavir Marboxil As A Single Dose

Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule

Expert Systems Announced Milestone in Traws Pharma's H5N1 Program; Tivoxavir Marboxil Shows Broad-Spectrum Efficacy In Phase 1 Trial With No Adverse Events; Single Dose Maintains Plasma Levels Above EC90 For Over 23 Days

Traws Pharma Stock Rockets On Promising H5N1 Bird Flu Treatment Results

Traws Pharma Shares Resume Trading

Traws Pharma Shares Halted On Circuit Breaker To The Upside; Stock Now Up 231.5%

Traws Pharma Shares Resume Trade

Traws Pharma Shares Halted To The Upside; Stock Now Up 172.51%

Traws Pharma Advances One-Dose Bird Flu Treatment with Results

Traws Pharma Q3 2024 GAAP EPS $(8.81) Misses $(6.12) Estimate, Sales $57.000M Beat $58.000K Estimate